IP Library › Granted Patent US 12,239,687
Granted Patent B2
US 12,239,687 · App. 17/535,267 · Granted Mar 4, 2025

Sustained release formulations using non-aqueous membrane emulsification

Inventors: Hunter Chen (New York, NY); Yiming Zhao (Great Neck, NY)
Assignee: Regeneron Pharmaceuticals, Inc.
A61K38/179A61K9/1658A61K9/1694
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,239,687
App. No.
17/535,267
Granted
Mar 4, 2025
Kind
B2
Abstract

Non-aqueous membrane emulsion methods for producing polymeric and polymer-coated microparticles are provided. Some embodiments provide methods for producing a sustained release or controlled release microparticle by combining micronized protein powder and a polymer into a hydrocarbon solvent to form a non-aqueous first solution, agitating the first non-aqueous solution to form a suspension, feeding the suspension into a dispersion pump, wherein the suspension is infused through a porous membrane into a continuous phase comprising a fluorocarbon liquid and a fluorosurfactant to form a hydrocarbon-in-fluorocarbon emulsion. The hydrocarbon solvent, the fluorocarbon liquid, and the fluorosurfactant are removed, and the microparticles are collected.

Claims (31)

1. A method of producing encapsulation efficient polymer-coated microparticles, wherein the method comprises:

combining micronized protein powder and a polymer into a hydrocarbon solvent to form a non-aqueous first solution, wherein the micronized protein powder comprises at least one selected from the group consisting of an antibody and an Fc-fusion protein;

agitating the first non-aqueous solution to form a suspension;

feeding the suspension to a dispersion cell, wherein the suspension is infused through a porous membrane into a continuous phase comprising a fluorocarbon liquid and a fluorosurfactant under a tangent flow of the continuous phase to form a hydrocarbon-in-fluorocarbon emulsion;

adding a hydrofluoroether to the hydrocarbon-in-fluorocarbon emulsion;

removing the hydrocarbon solvent to provide hardened microparticles; and

removing the fluorocarbon liquid to isolate the microparticles, wherein the microparticles comprise protein encapsulated within a matrix of polymer, wherein the protein is encapsulated at an efficiency of about 80% measured by protein loading in the polymer-coated microparticles or the theoretical protein loading from the first non-aqueous solution.

2. The method of claim 1 , further comprising the steps of removing residual fluorosurfactant from the microparticles by washing the microparticles in the fluorocarbon liquid and removing the fluorocarbon by vacuum and collecting the microparticles using a polyethersulfone membrane filter.

3. The method of claim 1 wherein the fluorocarbon liquid comprises a perfluoro C 5 -C 18 compound.

4. The method of claim 1 , wherein the hydrocarbon solvent is selected from the group consisting of dichloromethane, chloroform, toluene, ethyl acetate, tetrahydrofuran, or a combination thereof.

5. The method of claim 1 , wherein the fluorocarbon solution comprises 1,1,2,2,3,3,4,4,4-nonafluoro-N,N-bis (1,1,2,2,3,3,4,4,4-nonafluorobutyl) butan-1-amine.

6. The method of claim 1 , wherein the fluorosurfactant comprises Perfluoropolyether-b-Polyethylene glycol-b-Perfluoropolyether.

7. The method of claim 1 , wherein the polymer comprises polyorthoester (POE).

8. The method of claim 1 , wherein the polymer is selected from the group consisting of polylactic acid and poly (lactic-co-glycolic acid).

9. The method of claim 1 , wherein the hydrofluoroether is 2-(trifluoromethyl)-3-ethoxydodecafluorohexane.

10. The method of claim 1 , wherein the porous membrane is a fluorophilic-coated stainless steel membrane.

11. The method of claim 10 , wherein the pores of the porous membrane are 3 to 300 μm in diameter.

12. The method of claim 1 , wherein the fluorosurfactant is present in fluorocarbon liquid at about 0.1 to 5% w/v.

13. The method of claim 1 , wherein the protein powder to polymer ratio is 0.1%-30%.

14. The method of claim 1 , wherein the Fc-fusion protein is a vascular endothelial growth factor (VEGF) Trap fusion protein.

15. The method of claim 14 , wherein the VEGF-trap fusion protein is aflibercept.

16. A method of producing encapsulation efficient polymer-coated microparticles, wherein the method comprises:

combining a polymer and 1 to 30% w/w of total solid spray dried-protein suspended in a hydrocarbon solution to form a non-aqueous first solution, wherein the protein is selected from the group consisting of an antibody and an Fc-fusion protein;

agitating the first non-aqueous solution to form a suspension;

feeding the suspension to a dispersion pump, wherein the suspension is infused through a porous membrane into a continuous phase comprising a fluorocarbon liquid and 0.1 to 5.0% w/v fluorosurfactant under a tangent flow of the continuous phase to form a hydrocarbon-in-fluorocarbon emulsion;

removing the hydrocarbon solvent to provide hardened polymer-coated microparticles;

and removing the fluorocarbon liquid to isolate the microparticles, wherein the polymer-coated microparticles comprise protein encapsulated within a matrix of polymer, wherein the protein is encapsulated at an efficiency of about 80% measured by protein loading in the polymer-coated microparticles or the theoretical protein loading from the first non-aqueous solution.

17. The method of claim 16 , further comprising the step of adding a hydrofluoroether into the fluorocarbon liquid of the hydrocarbon-in-fluorocarbon emulsion prior to removing the hydrocarbon solvent.

18. The method of claim 16 , wherein the protein is aflibercept.

19. The method of claim 1 , where the protein is encapsulated at an efficiency of 80.7% measured by protein loading in the polymer-coated microparticles or the theoretical protein loading from the first non-aqueous solution.

20. The method of claim 16 , where the protein is encapsulated at an efficiency of 80.7% measured by protein loading in the polymer-coated microparticles or the theoretical protein loading from the first non-aqueous solution.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 7, 2025
From: ZHAO, YIMING; CHEN, HUNTER
To: REGENERON PHARMACEUTICALS, INC.
Reel/Frame 069772/0157 →
Continuity (2)
Provisional Application 63118264 · Nov 25, 2020
Related Publication 20220160828A1 · May 26, 2022
References Cited (77)
US 4210529A · Petersen · 1980 [cited by applicant]
US 4304767A · Heller et al. · 1981 [cited by applicant]
US 4764364A · Heller et al. · 1988 [cited by applicant]
US 5968543A · Heller et al. · 1999 [cited by applicant]
US 6063910A · Debenedetti et al. · 2000 [cited by applicant]
US 6927044B2 · Stahl et al. · 2005 [cited by applicant]
US 7087411B2 · Daly et al. · 2006 [cited by applicant]
US 7279159B2 · Daly et al. · 2007 [cited by applicant]
US 7396664B2 · Daly et al. · 2008 [cited by applicant]
US 7582298B2 · Stevens et al. · 2009 [cited by applicant]
US 7879984B2 · Martin et al. · 2011 [cited by applicant]
US 7998477B2 · Yakovlevsky et al. · 2011 [cited by applicant]
US 8043617B2 · Stevens et al. · 2011 [cited by applicant]
US 8062640B2 · Sleeman et al. · 2011 [cited by applicant]
US 8309088B2 · MacDonald et al. · 2012 [cited by applicant]
US 8586713B2 · Davis et al. · 2013 [cited by applicant]
US 8735095B2 · Martin et al. · 2014 [cited by applicant]
US 8871209B2 · Stitt et al. · 2014 [cited by applicant]
US 8945559B2 · Dix et al. · 2015 [cited by applicant]
US 9018356B2 · Sleeman et al. · 2015 [cited by applicant]
US 9079948B2 · Orengo et al. · 2015 [cited by applicant]
US 9132192B2 · Daly et al. · 2015 [cited by applicant]
US 9173880B2 · Dix et al. · 2015 [cited by applicant]
US 9228014B2 · Classon et al. · 2016 [cited by applicant]
US 9260515B2 · Stitt et al. · 2016 [cited by applicant]
US 9265827B2 · Wiegand et al. · 2016 [cited by applicant]
US 9302015B2 · Papadopoulos et al. · 2016 [cited by applicant]
US 9353176B2 · MacDonald et al. · 2016 [cited by applicant]
US 9402898B2 · Walsh et al. · 2016 [cited by applicant]
US 9447173B2 · Gurnett-Bander et al. · 2016 [cited by applicant]
US 9453072B2 · Murphy et al. · 2016 [cited by applicant]
US 9475875B2 · Kirshner et al. · 2016 [cited by applicant]
US 9540449B2 · Yancopoulos et al. · 2017 [cited by applicant]
US 9587029B2 · Okamoto et al. · 2017 [cited by applicant]
US 9637535B2 · Murphy et al. · 2017 [cited by applicant]
US 9657099B2 · Okamoto et al. · 2017 [cited by applicant]
US 9657102B2 · Smith et al. · 2017 [cited by applicant]
US 9718872B2 · Kyratsous et al. · 2017 [cited by applicant]
US 9771414B2 · Kyratsous et al. · 2017 [cited by applicant]
US 9795121B2 · Hu et al. · 2017 [cited by applicant]
US 9938345B2 · Papadopoulos et al. · 2018 [cited by applicant]
US 9987500B2 · Papadopoulos et al. · 2018 [cited by applicant]
US 10125188B2 · Gurnett-Bander et al. · 2018 [cited by applicant]
US 11135586B2 · Tang · 2021 [cited by examiner]
US 20140271681A1 · Martin et al. · 2014 [cited by applicant]
US 20150266966A1 · Smith et al. · 2015 [cited by applicant]
US 20160017029A1 · Walsh et al. · 2016 [cited by applicant]
US 20160114325A1 · Tang · 2016 [cited by examiner]
US 20190031741A1 · Gurnett-Bander et al. · 2019 [cited by applicant]
US 20220008505A1 · Zhao · 2022 [cited by examiner]
US 20220257707A1 · Zhao · 2022 [cited by examiner]
WO 2017075072A1 · 2017 [cited by applicant]
WO WO2017106716A1 · 2017 [cited by examiner]
WO 2017186073A1 · 2017 [cited by applicant]
WO WO2019077114A1 · 2019 [cited by examiner]
WO 2021108548A1 · 2021 [cited by applicant]
Byjus, Ester structure uses, obtained online at https://byjus.com/chemistry/ester/, downloaded on May 30, 2023. (Year: 2023). [cited by examiner]
Mana, Zohra, Yann Pellequer, and Alf Lamprecht. “Oil-in-oil microencapsulation technique with an external perfluorohexane phase.” International journal of pharmaceutics 338.1-2 (2007): 231-237. (Year: 2007). [cited by examiner]
Mana, Zohra et al. “Oil-in-oil microencapsulation technique with an external perfluorohexane phase.” International journal of pharmaceutics vol. 338,1-2 (2007): 231-7. doi:10.1016/j.ijpharm.2007.02.010 (Year: 2007). [cited by examiner]
Vladisavljević, Goran T, and Richard A Williams. “Recent developments in manufacturing emulsions and particulate products using membranes.” Advances in colloid and interface science vol. 113,1 (2005): 1-20. doi:10.1016/… [cited by examiner]
Homaeigohar, S. Sh, K. Buhr, and K. Ebert. “Polyethersulfone electrospun nanofibrous composite membrane for liquid filtration.” Journal of Membrane Science 365.1-2 (2010): 68-77.) (Year: 2010). [cited by examiner]
Ashkenazi et al., Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin. Proc Natl Acad Sci U S A. Dec. 1, 1991;88(23):10535-9. [cited by applicant]
Astete et al., Synthesis and characterization of PLGA nanoparticles. J Biomater Sci Polym Ed. 2006; 17(3):247-89. [cited by applicant]
Bustami et al., Generation of micro-particles of proteins for aerosol delivery using high pressure modified carbon dioxide. Pharm Res. Nov. 2000;17(11):1360-6. [cited by applicant]
Byrn et al., Biological properties of a CD4 immunoadhesin. Nature. Apr. 12, 1990;344(6267):667-70. [cited by applicant]
Heller et al., Poly(ortho esters)—from concept to reality. Biomacromolecules. Sep.-Oct. 2004;5(5):1625-32. [cited by applicant]
Heller, Ocular delivery using poly(ortho esters), Adv Drug Deliv Rev. Dec. 13, 2005;57(14):2053-62. [cited by applicant]
Hollenbaugh et al., Construction of immunoglobulin fusion proteins. Curr Protoc Immunol. May 2002;Chapter 10:Unit 10.19A. [cited by applicant]
Juang, Receptor-Fc fusion therapeutics, traps, and Mimetibody technology. Curr Opin Biotechnol. Dec. 2009;20(6):692-9. [cited by applicant]
Labet et al., Synthesis of polycaprolactone: a review. Chem Soc Rev. Dec. 2009;38(12):3484-504. [cited by applicant]
Martinac et al., Spray-dried chitosan/ethylcellulose microspheres for nasal drug delivery: swelling study and evaluation of in vitro drug release properties. J Microencapsul. Aug. 2005;22(5):549-61. [cited by applicant]
Raghuvanshi et al., Stabilization of dichloromethane-induced protein denaturation during microencapsulation. Pharm Dev Technol. May 1998;3(2):269-76. [cited by applicant]
Sinha et al., Poly-epsilon-caprolactone microspheres and nanospheres: an overview. Int J Pharm. Jun. 18, 2004;278(1):1-23. [cited by applicant]
Vladisavljevic et al., Recent developments in manufacturing emulsions and particulate products using membranes. Adv Colloid Interface Sci. Mar. 17, 2005;113(1):1-20. [cited by applicant]
Han et al., Insulin nanoparticle preparation and encapsulation into poly(lactic-co-glycolic acid) microspheres by using an anhydrous system. Int J Pharm. Aug. 13, 2009;378(1-2):159-66. [cited by applicant]
Holt et al., Synthesis of novel fluorous surfactants for microdroplet stabilisation in fluorous oil streams. Journal of Fluorine Chemistry. Mar. 2010; 131(3):398-407. [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/US2021/060800, dated Mar. 18, 2022, 15 pages. [cited by applicant]
Cited By (1)
US 12,667,603